A Commentary Updates on the Use of MLC901 (Neuroaidtm II/Nuraidtm II) in Patients with Cerebral Venous Sinus Thrombosis
DOI:
https://doi.org/10.61788/njn.v1i27.10Keywords:
MLC901, Cerebrovascular Venous Sinus Thrombosis, Anticoagulation Therapy, case reportsAbstract
Cerebral venous sinus thrombosis (CVST), which accounts for 0.5% of all strokes, primarily affects younger individuals and results in mild to moderate disability. While the prognosis is generally positive and most patients survive, there is a risk of potential disability, which may be severe in approximately 13% of CVST cases. MLC901 (NeuroAiDTM II/NurAidTM II), a combination of natural herbal ingredients, was administered as an add-on to anticoagulant therapy. MLC901 was shown to be safe and improved the clinical status of three CVST cases as reported in a previous publication. As an update to this previous three-case report, we have seen another patient in the clinic with a history of prior CVST 1.5 years ago, with symptoms of severe and persistent headache. We decided to initiate MLC901 in this patient at a dose of two capsules three times a day for 3 months in addition to anticoagulant therapy. The headaches were relieved without any observed side effects. These four cases highlight the potential beneficial effects of MLC901 on CVST.
References
Arsovska AA, Venketasubramanian N. Use of MLC901 in cerebral venous sinus thrombosis: Three case reports // World J Clin Cases. 2024 Jan 16;12(2):346-353. doi: 10.12998/wjcc.v12.i2.346
Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F. ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) // Stroke. 2004;35(3):664-670. doi: 10.1161/01.STR.0000117571.76197.26
Miranda B, Ferro JM, Canhão P, et al. ISCVT Investigators. Venous thromboembolic events after cerebral vein thrombosis // Stroke. 2010;41(9):1901-1906. doi: 10.1161/STROKEAHA.110.581223
Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis // Circulation. 2010 Jun 29;121(25):2740-6. doi: 10.1161/CIRCULATIONAHA.109.927046
Alajmi E, Zung J, Duquet-Armand M, Coutinho JM, Mandell DM. Prevalence of Venous Infarction in Patients with Cerebral Venous Thrombosis: Baseline Diffusion-Weighted MRI and Follow-Up MRI // Stroke. 2023 Jul;54(7):1808-1814. doi: 10.1161/STROKEAHA.122.042336
Schaller B, Graf R. Cerebral venous infarction: the pathophysiological concept // Cerebrovasc Dis. 2004;18(3):179-88. doi: 10.1159/000079939
Heurteaux, C. et al. NeuroAiD: Properties for Neuroprotection and Neurorepair // Cerebrovasc Dis. 2013;35(suppl 1):1-7.
Quintard, H. et al. MLC901, a Traditional Chinese Medicine protects the brain against global ischemia // Neuropharmacology. 2011;61:622-631.
Venketasubramanian N, Young SH, Tay SS, Umapathi T, Lao AY, Gan HH, et al. CHIMES-E Study Investigators. CHInese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study (CHIMES-E): A Multicenter Study of Long- Term Efficacy // Cerebrovasc Dis. 2015;39(5-6):309-18. doi: 10.1159/000382082
Arsovska A, Waldemsr B, Frasineanu AD, Marceanu M, Reisz D, Sarzyńska-Długosz Iwona, et al. The Use of MLC901in Combination with Anticoagulant among an Eastern European Cohort-Real World Data from NeuroAiD Safety Treatment Registry (NeST Registry) // Journal of Clin Research. 2023:7:2
Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx GJ. Long-term sequelae after cerebral venous thrombosis in functionally independent patients // J Stroke Cerebrovasc Dis. 2009 May-Jun;18(3):198-202. doi: 10.1016/j.jstrokecerebrovasdis.2008.10.004
Saposnik G, Bushnell C, Coutinho JM, Field TS et al. Diagnosis and management of cerebral venous thrombosis: A scientific statement from the American Heart Association // Stroke, 2024;55(3):77-90. doi: 10.1161/str.0000000000000456
Ferro JM, Coutinho JM, Dentali F, Kobayashi A, et al. RE-SPECT CVT Study Group. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial // JAMA Neurol. 2019 Dec 1;76(12):1457-1465. doi: 10.1001/jamaneurol.2019.2764
Field TS, Dizonno V, Almekhlafi MA, et al.; SECRET Investigators. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation with Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis // Stroke. 2023 Nov;54(11):2724-2736. doi: 10.1161/STROKEAHA.123.044113
Miceli G, Ciaccio AM, Tuttolomondo A. Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide // J. Clin. Med. 2025, 14, 2914. Doi: 10.3390/jcm14092914
Yaghi S, Shu L, Bakradze E, Salehi Omran S, Giles JA, Amar JY. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study // Stroke. 2022 Mar;53(3):728-738. doi: 10.1161/STROKEAHA.121.037541
Van de Munckhof A, Sánchez van Kammen M, Krzywicka K, Aaron S, Aguiar de Sousa D, Antochi F, Arauz A, et al. Direct oral anticoagulants for the treatment of cerebral venous thrombosis - a protocol of an international phase IV study // Front Neurol. 2023 Sep 14;14:1251581. doi:10.3389/fneur.2023.1251581
Venketasubramanian N, Kumar R, Soertidewi L, et al. The NeuroAiD Safe Treatment (NeST) Registry: a protocol // BMJ Open. 2015 Nov;5(11):e009866. DOI: 10.1136/bmjopen-2015-009866
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, et al. Adaptive designs in clinical trials: why use them, and how to run and report them // BMC Med. 2018 Feb 28;16(1):29. doi: 10.1186/s12916-018-1017-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National Association of Neurologists
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
